Alzamend Neuro Overview

  • Founded
  • 2016
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $232K
Latest Deal Amount

Alzamend Neuro General Information


Developer of immunotherapeutic treatment and vaccines designed to treat Alzheimer's diseases. The company has developed mutant-peptide immunotherapeutic (AL002) for use as a treatment or vaccine and a lithium-based ionic cocrystal therapy (AL001) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer, enabling patients to recover from Alzheimer's diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 201 Shipyard Way Suite E
  • Newport Beach, CA 92663
  • United States
+1 (844) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alzamend Neuro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 19-Apr-2019 $232K 00.000 Completed Startup
2. Angel (individual) 22-Aug-2017 000 Cancelled Startup
1. Angel (individual) 01-Jul-2016 $1M $1M Completed Startup
To view Alzamend Neuro’s complete valuation and funding history, request access »

Alzamend Neuro Executive Team (3)

Name Title Board Seat Contact Info
Stephan Jackman Chief Executive Officer
Kenneth Cragun Chief Financial Officer & Treasurer
Milton Ault III Founder & Chairman
To view Alzamend Neuro’s complete executive team members history, request access »

Alzamend Neuro Board Members (3)

Name Representing Role Since
Milton Ault III Self Founder & Chairman 000 0000
Philip Mansour Alzamend Neuro Board Member 000 0000
William Horne Alzamend Neuro Board Member 000 0000
To view Alzamend Neuro’s complete board members history, request access »

Alzamend Neuro Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial